Partial dopamine receptor agonists as newer atypical antipsychotics: Intrinsic activity appropriate for treatment of schizophrenic patients

Central Nervous System Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2007, Pages 156-165

  Odagaki, Yuji ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Aripiprazole; Atypical antipsychotics; Dopamine receptor; Dopamine system stabilizer; Intrinsic activity; Partial agonist; Presynaptic autoreceptor; Schizophrenia

Indexed keywords

7 [3 [4 (2,3 DIMETHYLPHENYL) 1 PIPERAZINYL]PROPOXY] 2(1H) QUINOLINONE; APOMORPHINE; ARIPIPRAZOLE; BROMOCRIPTINE; CHLORPROMAZINE; CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; N (2 CHLORO 6 METHYLERGOLIN 8ALPHA YL)PIVALAMIDE; OLANZAPINE; PEROSPIRONE; PIMOZIDE; PRAMIPEXOLE; PROPYLNORAPOMORPHINE; QUETIAPINE; RISPERIDONE; ROXINDOLE; SULPIRIDE; TALIPEXOLE; TERGURIDE; THIORIDAZINE; ZIPRASIDONE;

CLINICAL TRIAL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; GEOGRAPHIC DISTRIBUTION; HUMAN; NONHUMAN; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA;

EID: 34548422308     PISSN: 18715249     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152407781669125     Document Type: Review

References (92)

1. Seeman, P.; Kapur, S. In Current Issues in the Psychopharmacology of Schizophrenia, Breier, A.; Tran, P.V.; Herrea, J.M.; Tollefson, G.D.; Bymaster, F.P., Eds.; Lippincott Williams & Wilkins Healthcare: Philadelphia, 2001, pp. 73-84.
2. Kapur, S.; Remington, G. Biol. Psychiat., 2001, 50, 873.
3. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Arch. Gen. Psychiat., 1988, 45, 789.
4. Stahl, S.M. J. Clin. Psychiat., 2001, 62, 923.
5. Tamminga, C.A. J. Neural. Transm., 2002, 109, 411.
6. Hippius, H. J. Clin. Psychiat., 1999, 60 (Suppl. 12), 22.
7. Fleischhacker, W.W. Psychopharmacology, 2002, 162, 90.
8. Costall, B.; Naylor, R.J. Psychopharmacologia (Berl.), 1975, 43, 69.
9. Costall, B.; Naylor, R.J. Eur. J. Pharmacol., 1976, 40, 9.
10. Waddington, J.L.; O'Callaghan, E. CNS Drugs, 1997, 7, 341.
11. Meltzer, H.Y.; Matsubara, S.; Lee, J.-C. J. Pharmacol. Exp. Ther., 1989, 251, 238.
12. Remington, G. J. Psychiat. Neurosci., 2003, 28, 275.
13. Remington, G.; Kapur, S. Psychopharmacology, 2000, 148, 3.
14. Gerlach, J. Psychopharmacology, 2000, 148, 1.
15. Meltzer, H.Y. Psychopharmacology, 2000, 148, 16.
16. Tamminga, C.A. Psychopharmacology, 2000, 148, 20.
17. Roth, B.L.; Sheffler, D.; Potkin, S.G. Clin. Neurosci. Res., 2003, 3, 108.
18. Horacek, J.; Bubenikova-Valesova, V.; Kopecek. M.; Palenicek. T.; Dockery, C.; Mohr, P.; Höschl, C. CNS Drugs, 2006, 20, 389.
19. Arnt, J.; Skarsfeldt, T. Neuropsychopharmacology, 1998, 18, 63.
20. Gardner, D.M.; Baldessarini, R.J.; Waraich, P. Can. Med. Assoc. J., 2005, 172, 1703.
21. Burris, K.D.; Molski, T.F.; Xu, C.; Ryan, E.; Tottori, K.; Kikuchi, T.; Yocca, F.D.; Molinoff, P.B. J. Pharmacol. Exp. Ther., 2002, 302, 381.
22. Stahl, S.M. J. Clin. Psychiat., 2001, 62, 841.
23. Bolonna, A.A.; Kerwin, R.W. Br. J. Psychiat., 2005, 186, 7.
24. Weinberger, D.R. Arch. Gen. Psychiat., 1987, 44, 660.
25. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Am. J. Psychiat., 1991, 148, 1474.
26. Koeltzow, T.E.; Xu, M.; Cooper, D.C.; Hu, X.-T.; Tonegawa, S.; Wolf, M.E.; White, F.J. J. Neurosci., 1998, 18, 2231.
27. Meller, E.; Bohmaker, K.; Namba, Y.; Friedhoff, A.J.; Goldstein, M. Mol. Pharmacol., 1987, 31, 592.
28. Meller, E.; Enz, A.; Goldstein, M. Eur. J. Pharmacol., 1988, 155, 151.
29. Drukarch, B.; Stoof, J.C. Life Sci., 1990, 47, 361.
30. Del Zompo, M.; Bocchetta, A.; Piccardi, M.P.; Corsini, G.U. Prog. Brain Res., 1986, 65, 41.
31. Benkert, O.; Gründer, G.; Wetzel, H. Pharmacopsychiatry, 1992, 25, 254.
32. Benkert, O.; Müller-Siecheneder, F.; Wetzel, H. Eur. Neuropsychopharmacology, 1995, (Suppl.), 43.
33. Wetzel, H.; Benkert, O. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 1993, 17, 525.
34. Lahti, A.C.; Weiler, M.A.; Corey, P.K.; Lahti, R.A.; Carlsson, A.; Tamminga, C.A. Biol. Psychiat., 1998, 43, 2.
35. Oshiro, Y.; Sato, S.; Kurahashi, N.; Tanaka, T.; Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Nishi, T. J. Med. Chem., 1998, 41, 658.
36. Hirose, T.; Kikuchi, T. J. Med. Invest., 2005, 52 (Suppl.), 284.
37. Shapiro, D.A.; Renock, S.; Arrington, E.; Chiodo, L.A.; Liu, L.-X.; Sibley, D.R.; Roth, B.L.; Mailman, R. Neuropsychopharmacology, 2003, 28, 1400.
38. Hirose, T.; Uwahodo, Y.; Yamada, S.; Miwa, T.; Kikuchi, T.; Kitagawa, H.; Burris, K.D.; Altar, C.A.; Nabeshima, T. J. Psychopharmacol., 2004, 18, 375.
39. Kikuchi, T.; Tottori, K.; Uwahodo, Y.; Hirose, T.; Miwa, T.; Oshiro, Y.; Morita, S. J. Pharmacol. Exp. Ther., 1995, 274, 329.
40. Meltzer, H.Y.; Matsubara, S.; Lee, J.-C. Psychopharmacol. Bull., 1989, 25, 390.
41. Jordan, S.; Koprivica, V.; Chen, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. Eur. J. Pharmacol., 2002, 441, 137.
42. Newman-Tancredi, A.; Assié, M.-B.; Leduc, N.; Ormière, A.-M.; Danty, N.; Cosi, C. Int. J. Neuropsychopharmacol., 2005, 8, 341.
43. Odagaki, Y.; Toyoshima, R. Clin. Exp. Pharmacol. Physiol., 2007, 34, 462.
44. Millan, M.J. J. Pharmacol. Exp. Ther., 2000, 295, 853.
45. Bantick R.A.; Deakin, J.F.W.; Grasby, P.M. J. Psychopharmacol., 2001, 15, 37.
46. Wadenberg, M.-L. Neurosci. Biobehav. Rev., 1996, 20, 325.
47. Cosi, C.; Waget, A.; Rollet, K.; Tesori, V.; Newman-Tancredi, A. Brain Res., 2005, 1043, 32.
48. Deutsch, S.I.; Rosse, R.B.; Schwartz, B.L.; Mastropaolo, J. Clin. Neuropharmacol., 2001, 24, 43.
49. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W.L.; O'Laughlin, I.A.; Meltzer, H.Y. J. Neurochem., 2001, 76, 1521.
50. Li, Z.; Ichikawa, J.; Dai, J.; Meltzer, H.Y. Eur. J. Pharmacol., 2004, 493, 75.
51. Zocchi, A.; Fabbri, D.; Heidbreder, C.A. Neurosci. Lett., 2005, 387, 157.
52. Semba, J.; Watanabe, A.; Kito, S.; Toru, M. Neuropharmacology, 1995, 34, 785.
53. Jordan, S.; Koprivica, V.; Dunn, R.; Tottori, K.; Kikuchi, T.; Altar, C.A. Eur. J. Pharmacol., 2004, 483, 45.
54. Aihara, K.; Shimada, J.; Miwa, T.; Tottori, K.; Burris, K.D.; Yocca, F.D.; Horie, M.; Kikuchi, T. Brain Res., 2004, 1003, 9.
55. Cosi, C.; Carilla-Durand, E.; Assié, M.B.; Ormiere, A.M.; Maraval, M.; Leduc, N.; Newman-Tancredi, A. Eur. J. Pharmacol., 2006, 535, 135.
56. Inoue, A.; Miki, S.; Seto, M.; Kikuchi, T.; Morita, S.; Ueda, H.; Misu, Y.; Nakata, Y. Eur. J. Pharmacol., 1997, 321, 105.
57. Lawler, C.P.; Prioleau, C.; Lewis, M.M.; Mak, C.; Sibley, D.R.; Mailman, R.B. Neuropsychopharmacology, 1999, 20, 612.
58. Tadori, Y.; Miwa, T.; Tottori, K.; Burris, K.D.; Stark, A.; Mori, T.; Kikuchi, T. Eur. J. Pharmacol., 2005, 515, 10.
59. Inoue, T.; Domae, M.; Yamada, K.; Furukawa, T. J. Pharmacol. Exp. Ther., 1996, 277, 143.
60. Momiyama, T.; Amano, T.; Todo, N.; Sasa, M. Eur. J. Pharmacol., 1996, 310, 1.
61. Amamo, T.; Matsubayashi, H.; Momiyama, T.; Ishihara, K.; Todo, N.; Sasa, M. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 1995, 19, 105.
62. Matsubayashi, H.; Amano, T.; Sasa, M. Psychopharmacology, 1999, 146, 139.
63. Yamada, S.; Harano, M.; Yokoo, H.; Tanaka, M. J. Pharm. Pharmacol., 1997, 49, 206.
64. Semba, J.; Sakai, M.; Miyoshi, R.; Mataga, N.; Fukamauchi, F.; Kito, S. Neurochem. Int., 1996, 29, 435.
65. Inoue, A.; Seto, M.; Sugita, S.; Hide, I.; Hirose, T.; Koga, N.; Kikuchi, T.; Nakata, Y. Mol. Brain Res., 1998, 55, 285.
66. Nakai, S.; Hirose, T.; Uwahodo, Y.; Imaoka, T.; Okazaki, H.; Miwa, T.; Nakai, M.; Yamada, S.; Dunn, B.; Burris, K.D.; Molinoff, P.B.; Tottori, K.; Altar, C.A.; Kikuchi, T. Eur. J. Pharmacol., 2003, 472, 89.
67. McGavin, J.K.; Goa, K.L. CNS Drugs, 2002, 16, 779.
68. Ozdemir, V.; Fourie, J.; Özdener, F. Curr. Opin. Invest. Drugs, 2002, 3, 113.
69. Buckley, P.F. Drugs Today, 2003, 39, 145.
70. Taylor, D.M. Int. J. Clin. Pract., 2003, 57, 49.
71. Bowles, T.M.; Levin, G.M. Ann. Pharmacother., 2003, 37, 687.
72. Keck, P.Jr.; McElroy, S.L. Exp. Opin. Invest. Drugs, 2003, 12, 655.
73. Lieberman, J.A. CNS Drugs, 2003, 18, 251.
74. DeLeon, A.; Patel, N.C.; Crismon, M.L. Clin. Ther., 2004, 26, 649.
75. Green, B. Curr. Med. Res. Opin., 2004, 20, 207.
76. Davies, M.A.; Sheffler, D.J.; Roth, B.L. CNS Drug Rev., 2004, 10, 317.
77. Naber, D.; Lambert, M. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 2004, 28, 1213.
78. Gupta, S.; Masand, P. Ann. Clin. Psychiat., 2004, 16, 155.
79. Harrison, T.S.; Perry, C.M. Drugs, 2004, 64, 1715.
80. Fleischhacker, W.W. Expert Opin. Pharmacother., 2005, 6, 2091.
81. Kinghorn, W.A.; McEvoy, J.P. Expert Rev. Neurother., 2005, 5, 297.
82. El-Sayeh, H.G.; Morganti, C. Cochrane Database of Systematic Reviews, 2006, Issue 2. Art. No.: CD004578. DOI: 10.1002/14651858. CD004578.pub3.
83. Hoyer, D.; Boddeke, H.W.G.M. Trends Pharmacol. Sci., 1993, 14, 270.
84. Kenakin, T. Trends Pharmacol. Sci., 1999, 20, 400.
85. Kenalin, T. Nature Rev. Drug Discov., 2002, 1, 103.
86. Odagaki, Y.; Toyoshima, R. Prog. Neuro-Psychopharmacol. Biol. Psychiat., 2006, 30, 1304.
87. Yokoi, F.; Gründer, G.; Biziere, K.; Stephane, M.; Dogan, A.S.; Dannals, R.F.; Ravert, H.; Suri, A.; Bramer, S.; Wong, D.F. Neuropsychopharmacology, 2002, 27, 248.
88. Farde, L.; Wiesel, F.-A.; Halldin, C.; Sedvall, G. Arch. Gen. Psychiat., 1988, 45, 71.
89. Farde, L.; Nordström, A.-L.; Wiesel, F.-A.; Pauli, S.; Halldin, C.; Sedvall, G. Arch. Gen. Psychiat., 1992, 49, 538.
90. Gründer, G.; Carlsson, A.; Wong, D.F. Arch. Gen. Psychiat., 2003, 60, 974.
91. Natesan, S.; Reckless, G.E.; Nobrega, J.N.; Fletcher, P.J.; Kapur, S. Neuropsychopharmacology, 2006, 31, 1854.
92. Burstein, E.S.; Ma, J.; Wong, S.; Gao, Y.; Pharm, E.; Knapp, A.E.; Nash, N.R.; Olsson, R.; Davis, R.E.; Hacksell, U.; Weiner, D.M.; Brann, M.R. J. Pharmacol. Exp. Ther., 2006, 315, 1278.